Lakefront Biotherapeutics NV Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/21/2026)
| Balance Sheet | Total Assets | 3,406,520,000.00 | ROE | 94.99 % |
| Balance Sheet | Total Equity | 3,235,868,000.00 | ROA | 9.42 % |
| Cashflow | Capital Expenditures | -13,704,000.00 | P/FCF | -8.14 |
| Cashflow | Free Cash Flow | -210,712,000.00 | – | – |
| Cashflow | Operating Cash Flow | -197,008,000.00 | P/CF | -8.71 |
| Income | Earnings per Share (diluted) | 4.87 | Div. Yield | – |
| Income | Net Income | 319,492,000.00 | P/E | 5.35 |
| Income | Shares Outstanding | 65,890,000.00 | P/B | 0.53 |
| Income | Total Revenue | 1,112,250,000.00 | P/S | 1.54 |
Ratios calculated on: 10/14/2026
Company Description
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn\'s disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.glpg.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more